Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on Wednesday, October 19, 2022 at 2:00 p.m. Eastern (11:00 a.m. Pacific).

During the event, Chief Executive Officer (CEO) Benjamin Lightburn and Chief Science Officer (CSO) Ryan Moss will discuss Filament’s recent progress including intellectual property developments, a successful financing, an FDA-approved clinical trial in partnership with the University of California San Francisco, and plans for future growth.

The discussion will be followed by a question-and-answer session with the Company’s senior management team.

WHO:             Benjamin Lightburn, CEO, and Ryan Moss, CSO
WHEN:           Wednesday, August 12, 2021 at 2:00 p.m. EST (11:00 a.m. PST)
WHERE:        RSVP to to receive access details.

A recording of the webcast will be available on the investor section of the Company’s website following the event.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.